gram-negative

(redirected from Gram-negative bacterial infections)
Also found in: Dictionary, Thesaurus, Medical.

gram-negative

[′gram¦neg·əd·iv]
(microbiology)
Of bacteria, decolorizing and staining with the counterstain when treated with Gram's stain.
References in periodicals archive ?
Coverage of the Gram-Negative Bacterial Infections pipeline on the basis of route of administration and molecule type.
Devise corrective measures for pipeline projects by understanding Gram-Negative Bacterial Infections pipeline depth and focus of Indication therapeutics.
Cubist is developing CXA-201 as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa.
This press release contains forward-looking statements, including statements regarding the potential acquisition of Calixa by Cubist, CXA-201 as a treatment of serious Gram-negative bacterial infections in the hospital, the timing of filing of an NDA for CXA-201, and the timing of the closing of the acquisition of Calixa Therapeutics.
Phase I human testing of rBPI-23 has been conducted, and the product is being evaluated for use in the treatment of a range of conditions related to gram-negative bacterial infections including sepsis;
There is an urgent need for the development of new antibiotics to treat these and other gram-negative bacterial infections," said Steven Porter, Chairman and CEO of Ceragenix Pharmaceuticals.
SIGA is designing and developing inhibitors of the assembly of bacterial pili as potential antibiotic agents for the treatment of gram-negative bacterial infections, including bladder infections, pneumonia and middle ear infections.
General gram-negative bacterial infections: Only a few decades ago, gram-negative bacterial infections were relatively rare.
The study was conceived as a proof of concept for diseases involving gram-negative bacterial infections with high circulating levels of bacterial endotoxin, and the results have been very enlightening.
Supports Development of Novel Compounds to Treat Multi-Drug Resistant Gram-Negative Bacterial Infections -
Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for garenoxacin, a new type of broad-spectrum quinolone antibiotic for treating Gram-positive and Gram-negative bacterial infections, including those caused by anaerobic organisms and resistant bacterial strains.
Abstracts feature CUBICIN[R] (daptomycin for injection), and pipeline candidates CXA-201, which is being developed for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, and CB-183,315, a potent, oral, bactericidal lipopeptide, which is being developed for the treatment of Clostridium difficile-associated diarrhea (CDAD).

Full browser ?